about
A novel self-replicating chimeric lentivirus-like particleHIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategiesLive attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaquesAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesFrom plasmids to protection: a review of DNA vaccines against infectious diseasesMolecular and epidemiological characterization of HIV-1 subtypes among Libyan patients.Development of replication-competent viral vectors for HIV vaccine delivery.Expression of CD154 by a simian immunodeficiency virus vector induces only transitory changes in rhesus macaques.Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virusDivergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from diseaseNon-human primate models for AIDS vaccine research.Envelope determinants of equine lentiviral vaccine protection.Construction and characterization of chimeric BHIV (BIV/HIV-1) viruses carrying the bovine immunodeficiency virus gag gene.Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissuesViral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.Even attenuated bovine leukemia virus proviruses can be pathogenic in sheepConstruction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolutionHIV-1 Nef: at the crossroadsDevelopment of prophylactic vaccines against HIV-1.Macaque models of human infectious disease.Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaquesMacaca mulatta, fascicularis and nemestrina in AIDS vaccine development.HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.Possible applications for replicating HIV 1 vectorsHuman immunodeficiency virus antibodies and the vaccine problem.Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses.Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen.Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.Immunity and protection by live attenuated HIV/SIV vaccines.In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q24611993-C798AE00-03F4-4460-80A4-B1A9E6EAA7A8Q26799624-5CFC1097-2370-4E78-BE99-893842ACD5DBQ27305234-8248E19F-8192-4ABA-A4BC-39732695EADEQ27489000-7EFF1116-89D4-4746-A01F-C8B414D63F06Q28250092-6719CDCC-38C6-4C9F-A601-38B60BB0FFB5Q33617645-368238E7-5267-4D98-8D4F-D053DFC69A09Q33694226-B3ACEA53-EF68-4310-B26F-AE0BBC83848AQ33724139-0D9A5AD8-659C-4EB3-839D-51ADB2F7D8FCQ33843308-E5194AA5-28C3-4B4F-8B34-F7223855D5D1Q34007084-77CF987F-C822-47E8-8DE8-380634B362F7Q34196463-44DABCF7-30FD-4CA4-86C4-A2D68BFCDA9CQ34380211-88763250-9A1C-40BA-9EF8-E8E980519471Q34715769-7A5B9FDE-0643-4BC4-9BE4-3BC62FCE5D54Q34778836-7F4989F1-25B7-457D-BDF6-866D5E7D66AFQ35010631-6892A383-8C85-4935-9048-40D60E03B820Q35233022-B71AF3DC-69A4-49E6-9542-98AE1389FBE3Q35948073-9214F0BC-DFCF-4EC7-90B2-96F36F87404BQ36098921-3CDB7DC1-C38F-4AE1-90DD-21B073777F1FQ36099319-787200A8-01C7-43BE-8D69-7599FD668E47Q36385484-0DA8A5A9-B95D-433C-8FB3-806F8819A6BBQ36447540-2F1C81C7-AEEF-4D5A-8A4B-2A910862A64DQ36600380-B231CAED-4036-4EEF-B9CD-AF09AA0752E2Q36743410-F785346D-AF48-4BE2-8310-80A6B5337BFEQ36926697-82490580-7195-4480-9A61-51432820A46BQ37042563-B62764D5-86E7-4C95-AB0F-BEFDE570BAF2Q37103536-F7B9C2D2-E48E-4160-91A3-586035DA5D77Q37113804-3FEBE5E1-53A8-4A6A-96EF-DC221E944E4FQ37316026-816B5540-44B5-469D-B652-654C49DC4DC7Q37755873-DB2BBF66-3805-4331-9D03-7B76AA5A8650Q37768033-CF6FB79F-4C24-42C8-9909-2A6EC46CB32BQ38192126-1D74419C-DEFD-48A6-A155-273902514035Q38619108-84AECA08-76AE-4F42-A327-9801F2B8BF1FQ39395958-FD110F9C-3307-4516-9CE0-A8073967DA7AQ41923238-5F50AB13-9A9D-45B9-8A8D-61A27193C76DQ43213534-BC20D210-236E-4C02-B204-155E76A53C4BQ45385363-47AE2A64-066D-438B-9A04-447B075AE497Q48133582-0939B751-26DA-467B-85D0-6684AF2DEBC5Q56993265-2C66FC8E-DDF8-48AB-885D-08AF1AC0546E
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Live attenuated HIV vaccines: pitfalls and prospects.
@ast
Live attenuated HIV vaccines: pitfalls and prospects.
@en
type
label
Live attenuated HIV vaccines: pitfalls and prospects.
@ast
Live attenuated HIV vaccines: pitfalls and prospects.
@en
prefLabel
Live attenuated HIV vaccines: pitfalls and prospects.
@ast
Live attenuated HIV vaccines: pitfalls and prospects.
@en
P1476
Live attenuated HIV vaccines: pitfalls and prospects.
@en
P2093
James B Whitney
Ruth M Ruprecht
P356
10.1097/00001432-200402000-00004
P577
2004-02-01T00:00:00Z